Australia Steps Up Priority Review And Faster Assessment Plans
Executive Summary
The Therapeutic Goods Administration is seeking feedback on proposals for a priority-review pathway and a system for designating Australian conformity assessment bodies. Both efforts promise to speed products to market and might also involve new fees for industry.
You may also be interested in...
No Delays Expected As Australian Bill On Faster Drug Approvals Goes To Parliament
The Australian parliament has held its first reading of a bill that will implement a number of new measures in the pharmaceutical area, including two new expedited drug approval pathways and a risk-based approach to variations.
Australia Accepts Three Approval Pathways, Defers Registry For High-Risk Devices
The Australian government plans to introduce a series of regulatory reforms for devices and drugs over a period of three years, including moves to speed up access to innovative devices and to better leverage assessments by overseas regulators. The changes may include some recovery of costs from industry.
Australia to ease regulatory burden for devices and drugs
A small group of experts is to conduct an independent assessment of Australia's Therapeutic Goods Administration with a view to streamlining the agency's regulatory processes for medicines and medical devices, improving access to medicines, and boosting productivity and competitiveness.